TABLE 3.
Neutralization susceptibility of chimeric envelope pseudoviruses prepared from AIIMS_329 and AIIMS_330 to autologous plasma from 117 months and V2 glycan bnAb PG9a
| Twin and V1V2 loop | Envelope backbone | 117-mo autologous plasma |
PG9 |
||||
|---|---|---|---|---|---|---|---|
| ID50 |
Fold change in ID50 | IC50 |
Fold change in IC50 | ||||
| Envelope backbone | Chimeric envelope | Envelope backbone | Chimeric envelope | ||||
| AIIMS_329 | |||||||
| 329.15.A1 | 329.14.B1 | 1,124 | 151 | 7.42 | <0.02 | >10 | >500 |
| 329.15.B1 | 329.14.B1 | 1,124 | 345 | 3.25 | <0.02 | 6.91 | >345 |
| 329.16.C1 | 329.14.B1 | 1,124 | 137 | 8.21 | <0.02 | 7.42 | >371 |
| 329.16.D5 | 329.14.B1 | 1,124 | 156 | 7.21 | <0.02 | >10 | >500 |
| 329.14.B1 | 329.16.D5 | <100 | 363 | >3.63 | >10 | 2.65 | >3.77 |
| AIIMS_330 | |||||||
| 330.15.C36 | 330.14.A20 | 1,427 | 108 | 13.21 | 1.11 | 8.92 | 8.03 |
| 330.15.D36 | 330.14.A20 | 1,427 | 112 | 12.81 | 1.11 | 7.91 | 7.12 |
| 330.15.E36 | 330.14.A20 | 1,427 | <100 | >14.27 | 1.11 | 9.96 | 8.97 |
| 330.16.A2 | 330.14.A20 | 1,427 | <100 | >14.27 | 1.11 | 3.64 | 3.28 |
| 330.16.D4 | 330.14.A20 | 1,427 | <100 | >14.27 | 1.11 | 7.69 | 6.92 |
| 330.16.E6 | 330.14.A20 | 1,427 | 699 | 2.04 | 1.11 | 0.86 | 0.77 |
| 330.16.H2 | 330.14.A20 | 1,427 | <100 | >14.27 | 1.11 | 3.99 | 3.59 |
| 330.14.A20 | 330.16.D4 | 151 | 635 | 4.21 | >10 | 3.34 | >2.99 |
a
Given are the respective ID50 (50% inhibitory concentrations [IC50] for PG9) and fold change in ID50 (50% inhibitory concentrations for PG9) for the V1V2 loop-swapped chimeric envelopes of AIIMS_329 and AIIMS_330.